» Articles » PMID: 34491335

Low Coronary Flow Relative to Myocardial Mass Predicts Heart Failure in Symptomatic Hypertensive Patients with No Obstructive Coronary Artery Disease

Overview
Journal Eur Heart J
Date 2021 Sep 7
PMID 34491335
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: The transition from hypertension to heart failure (HF) remains poorly understood. We hypothesized that insufficient perfusion to match global metabolic demand, reflected by a low ratio of myocardial blood flow to global myocardial mass, may be a HF risk marker.

Methods And Results: A retrospective cohort (n = 346) of patients with hypertension who underwent clinical positron emission tomography (PET) myocardial perfusion imaging for chest pain and/or dyspnoea at Brigham and Women's Hospital (Boston, MA, USA) were studied. Patients without obstructive coronary artery disease by history or PET perfusion (summed stress score <3), HF, cardiomyopathy, or ejection fraction (EF) <40% were followed for HF hospitalization (primary outcome), all-cause death, and their composite. Myocardial blood flow, left ventricular (LV) mass, volumes, and EF were obtained from PET, and a 'flow/mass ratio' was determined as hyperaemic myocardial blood flow over LV mass indexed to body surface area. A lower flow/mass ratio was independently associated with larger end-diastolic (β = -0.44, P < 0.001) and end-systolic volume (β = -0.48, P < 0.001) and lower EF (β = 0.33, P < 0.001). A flow/mass ratio below the median was associated with an adjusted hazard ratio of 2.47 [95% confidence interval (CI) 1.24-4.93; P = 0.01] for HF hospitalization, 1.95 (95% CI 1.12-3.41; P = 0.02) for death, and 2.20 (95% CI 1.39-3.49; P < 0.001) for the composite.

Conclusion: An integrated physiological measure of insufficient myocardial perfusion to match global metabolic demand identifies subclinical hypertensive heart disease and elevated risk of HF and death in symptomatic patients with hypertension but without flow-limiting coronary artery disease.

Citing Articles

Hypertensive Heart Disease: Mechanisms, Diagnosis and Treatment.

Huang X, Hu L, Long Z, Wang X, Wu J, Cai J Rev Cardiovasc Med. 2024; 25(3):93.

PMID: 39076964 PMC: 11263885. DOI: 10.31083/j.rcm2503093.


Connexin43, A Promising Target to Reduce Cardiac Arrhythmia Burden in Pulmonary Arterial Hypertension.

Sykora M, Szeiffova Bacova B, Andelova K, Benova T, Martiskova A, Kurahara L Int J Mol Sci. 2024; 25(6).

PMID: 38542257 PMC: 10970272. DOI: 10.3390/ijms25063275.


Hypertensive Heart Disease: A Narrative Review Series-Part 3: Vasculature, Biomarkers and the Matrix of Hypertensive Heart Disease.

Nemtsova V, Vischer A, Burkard T J Clin Med. 2024; 13(2).

PMID: 38256639 PMC: 10816030. DOI: 10.3390/jcm13020505.


Body Composition, Coronary Microvascular Dysfunction, and Future Risk of Cardiovascular Events Including Heart Failure.

Souza A, Rosenthal M, Moura F, Divakaran S, Osborne M, Hainer J JACC Cardiovasc Imaging. 2023; 17(2):179-191.

PMID: 37768241 PMC: 10922555. DOI: 10.1016/j.jcmg.2023.07.014.


Microvascular endothelial dysfunction in skin is associated with higher risk of heart failure with preserved ejection fraction in women with type 2 diabetes: the Hoorn Diabetes Care System Cohort.

Canto E, van Deursen L, Hoek A, Elders P, den Ruijter H, Velden J Cardiovasc Diabetol. 2023; 22(1):234.

PMID: 37658327 PMC: 10474683. DOI: 10.1186/s12933-023-01935-z.


References
1.
Rastogi A, Novak E, Platts A, Mann D . Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction. Eur J Heart Fail. 2017; 19(12):1597-1605. PMC: 5730502. DOI: 10.1002/ejhf.879. View

2.
Rischpler C, Higuchi T, Fukushima K, Javadi M, Merrill J, Nekolla S . Transient ischemic dilation ratio in 82Rb PET myocardial perfusion imaging: normal values and significance as a diagnostic and prognostic marker. J Nucl Med. 2012; 53(5):723-30. DOI: 10.2967/jnumed.111.097600. View

3.
Kiko T, Yoshihisa A, Yokokawa T, Misaka T, Yamada S, Kaneshiro T . Direct comparisons of left ventricular volume and function by simultaneous cardiac magnetic resonance imaging and gated 13N-ammonia positron emission tomography. Nucl Med Commun. 2020; 41(4):383-388. DOI: 10.1097/MNM.0000000000001149. View

4.
Kjaer A, Meyer C, Wachtell K, Olsen M, Ibsen H, Opie L . Positron emission tomographic evaluation of regulation of myocardial perfusion in physiological (elite athletes) and pathological (systemic hypertension) left ventricular hypertrophy. Am J Cardiol. 2005; 96(12):1692-8. DOI: 10.1016/j.amjcard.2005.07.090. View

5.
Taqueti V, Solomon S, Shah A, Desai A, Groarke J, Osborne M . Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction. Eur Heart J. 2018; 39(10):840-849. PMC: 5939665. DOI: 10.1093/eurheartj/ehx721. View